Clinical Service in Interventional Oncology

Why even PDT®
Cancer care currently lacks of efficacy, safety, overall survival, QoL and cost effectiveness.
Company’s unique capacity to solve the problem leaded to Photonic Tumor Therapy and a worldwide IP portfolio of patents and trademarks.
Intensive R&D over ten yrs ended in two non-toxic components - light and oxygen.
Patients’ individually administered, inert photon transformer identifies abnormal cell growth and locates therein temporarily.
Diseases’ individually modulated laser light induces toxic/singlet oxygen - no ROS - killing proliferated cells by apoptosis and necrosis.
Photonic Tumor Therapy is available as CE-certified, hands-on “Clinical Service Application Support”.
Applicable for precursors, developed & metastatic cancers in the biliary system, bladder, bronchus, cardia, cervix uteri, colon, esophagus/Barrett's, lung, pancreas, rectum.
Safe and effective in 400+ applications, extended survival - 700+ yrs up to now - to standard, QoL, no procedure related mortality.
Reimbursed in major markets, flat rate, pay-per-use.
Global roll out under way.

Referenzkunden

Medical University of Vienna, University Hospital, Clinical Department of Internal Medicine III, Gastroenterology & Hepatology
Medical University of Vienna, University Hospital, Clinical Department of Internal Medicine II
Medical University of Graz, University Hospital, Clinical Department of Internal Medicine, Division of Gastroenterology & Hepatology
etc.

Schlagworte

Website

http://www.pdt.at